Big Pharma teams up to tackle 'superbugs'; Indian drugmakers sign up to copy BMS hep C drug;

@FiercePharma: Vaccines present 'biggest breakthrough' in animal health: Report. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Poland says Mylan halted production at Agila Specialties plant after inspectors found issues. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals. FiercePharma article | Follow @CarlyHFierce

> Pharma giants including GlaxoSmithKline ($GSK) and Merck & Co. ($MRK) are teaming up to accelerate R&D on drugs and devices to treat antibiotic-resistant infections. Release

> The Medicines Patent Pool signed up four Indian drugmakers to manufacture copies of Bristol-Myers Squibb's ($BMY) hepatitis C drug daclatasvir under a license designed to give patients in low- and middle-income countries access to antiviral treatment. Report

> A New Jersey man sued Bristol-Myers Squibb and Otsuka Pharmaceuticals, claiming that their psychiatric drug Abilify caused him to develop a compulsive gambling habit. Report

Medical Device News

@FierceMedDev: IBM bets its future on machine learning and Watson Health. Article | Follow @FierceMedDev

@EmilyWFierce: Drug and diagnostic cos are teaming up to develop new antibiotics for superbugs. More from the WSJ (sub. req.) | Follow @EmilyWFierce

> GSK, Qualcomm rumored to form $1B med tech joint venture. Report

> Pelvalon launches vaginal insert for nonsurgical treatment of fecal incontinence. Story

> bioMérieux's bioTheranostics unit embarks on solo act with $32M in tow. Article

Biotech News

@FierceBiotech: ICYMI: Abingworth tees up a unique, $105M co-development fund for PhIII deals. Article | Follow @FierceBiotech

@JohnCFierce: J&J halts a depression program in the shadow of a fatal French trial. News | Follow @JohnCFierce

@DamianFierce: the FDA is handling its breakup with $SRPT very childishly. just be honest and direct and maybe you can stay friends. | Follow @DamianFierce

> GlaxoSmithKline scientists accused of stealing drug R&D secrets for China scheme. Report

> FDA snow day delays review of Sarepta's Duchenne drug. Item

> Alkermes slammed as top depression drug fails two PhIIIs. Article

CRO News

> Parexel moves to buy a pharma consulting firm. News

> Catalent extends its clinical supply biz into Japan. More

> BioClinica buys into cost management with its latest deal. Report

> Biosimilars developer Celltrion taps Medidata for trial tech. Story

> French CRO Biotrial tries to move forward after disastrous clinical study. Article

Pharma Manufacturing News

> China ingredient maker's plant found in 'devastated state' by authorities. News

> Catalent expanding Japanese manufacturing site to offer clinical services. Item

> FDA says microbial contamination found at Montana Compounding. Report

> FDA bans products from another Chinese plant. Story

> Pfizer reportedly striking deal with Polysan for Russian production. Article

Pharma Asia News

> Japan's Daiichi Sankyo, Coherus become players in Enbrel biosimilar race. More

> China FDA plowed through trial and new drug applications in 2015, commissioner says. Report

> Japan's Chiyoda plans on big growth in drug plant building. Story

> AstraZeneca survives Onglyza compulsory license challenge in India. Article

> Medical reps in India face the boot from doctors' offices. Report

And Finally... Yale University researchers say they've developed a questionnaire to predict which patients will respond to particular antidepressants. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.